Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation

Jose P. Lopez-Lopez; Patricio Lopez-Jaramillo

doi:10.1016/j.medj.2024.11.010

Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation

Jose P. Lopez-Lopez, Patricio Lopez-Jaramillo

Research output: Articles / Notes › Comment/debate

Abstract

The GMRx2 trial¹ in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.

Original language	English
Pages (from-to)	1461-1462
Number of pages	2
Journal	Med
Volume	5
Issue number	12
DOIs	https://doi.org/10.1016/j.medj.2024.11.010
State	Published - 13 Dec 2024
Externally published	Yes

Access to Document

10.1016/j.medj.2024.11.010

Cite this

@article{f247146c72834b62969cef458b0fd616,

title = "Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation",

abstract = "The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.",

author = "Lopez-Lopez, {Jose P.} and Patricio Lopez-Jaramillo",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2024",

month = dec,

day = "13",

doi = "10.1016/j.medj.2024.11.010",

language = "Ingl{\'e}s",

volume = "5",

pages = "1461--1462",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step

T2 - Implementation

AU - Lopez-Lopez, Jose P.

AU - Lopez-Jaramillo, Patricio

PY - 2024/12/13

Y1 - 2024/12/13

N2 - The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.

AB - The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.

UR - http://www.scopus.com/inward/record.url?scp=85211323774&partnerID=8YFLogxK

U2 - 10.1016/j.medj.2024.11.010

DO - 10.1016/j.medj.2024.11.010

M3 - Comentario/Debate

AN - SCOPUS:85211323774

SN - 2666-6359

VL - 5

SP - 1461

EP - 1462

JO - Med

JF - Med

IS - 12

ER -

Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this